[1] Tai CJ, Liu FY, Liang JA, et al. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma[J]. Anticancer Res, 2002, 22(6B): 3793-6. [2] Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1in advanced stage non-small cell lung cancer: an early measure of response[J]. Clin Cancer Res, 2003, 9(5): 1728-33. [3] Karnak D, Ulubay G, Kayacan O, et al. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas [J].Lung, 2001, 179(1): 57-65. [4] Ychou M, Khemissa-Akouz F, Kramar A, et al. A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma[J]. Bull Cancer, 2001, 88(10): 1023-7. [5] Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125,CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors [J].Tumour Biol, 2003, 24(4): 209-18. [6] Ando S, Kimura H, Iwai N, et al. Positive reactions for both Cyfra21-1and CA125 indicate worst prognosis in non-small cell lung cancer[J]. Anticancer Res, 2003, 23(3C): 2869-74. [7] Giovanella L, Ceriani L, Giardina G, et al. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer:comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA) [J]. Clin Chem Lab Med, 2002, 40(3): 298-303. [8] Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer[J]. Anticancer Res, 2004, 24(3B): 1941-6. [9] Schneider J, Velcovsky HG, Morr H, et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer [J]. Anticancer Res, 2000, 20(6D): 5053-8. [10] Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer [J]. Respiration,2002, 69(1): 25-9. |